Immune check-point blockade with monoclonal antibodies directed against CTLA-4, PD-1 and PD-L1 are revolutionizing treatment paradigms across multiple tumor types. These therapies have shown striking antitumor activity in an increasing number of solid tumors and hematologic malignancies. Bladder cancer, however, has long been known to be immune-responsive.
This phase II trial studies how well atezolizumab works in treating patients with non-muscle invasive bladder cancer that has come back and has not responded to treatment with Bacillus Calmette-Guerin (BCG). Monoclonal antibodies, such as atezolizumab, may block specific proteins found on white blood cells which may strengthen the immune system and control tumor growth.